I am a Senior scientist at AlzeCure Pharma, a Swedish pharmaceutical company focusing on the research and development of innovative and efficacious treatments for Alzheimer’s disease (AD) and pain. After my PhD in Biosciences, I worked as a Postdoc at Karolinska Institute in Sweden within the neuroscience field and gained expertise in several areas of neurobiology, cell metabolism and oxidative stress. My research has been focused on understanding the biological mechanisms behind prevention and risk factors for AD. Since 2019, I work within the Discovery and Research department at AlzeCure Pharma and my main goal is to characterize the chemical and biological properties of new drug candidates in in vitro and in vivo systems.

Dr. Pasinetti is the Saunders Family Chair and Professor of Neurology, and Chief of the Neurodiagnostics and Neurotherapeutics division of the Friedman Brain Institute at The Icahn School of Medicine at Mount Sinai. He is also the Director of Basic and Biomedical Research and Training Program at GRECC of the James J. Peters Veterans Affairs Medical Center, Bronx, NY. He has a strong record of successful and productive research endeavors exploring the mechanisms associated with mood disorders and neurodegenerative conditions. Over the past 30 years, his research has focused on developing model systems of brain disorders in order to better understand and clarify their underlying mechanisms. His previous experience as director of the Center of Excellence for Research on CAM (P01) focused on how polyphenol metabolites interact with multiple neuropathological features in Alzheimer’s disease, such as synaptic maladaptation, Aβ neurotoxicity, and disruption of neuronal microtubule-associated tau proteins leading to impaired axonal transport. In the past few years, his research has been tailored to understanding how psychological stress and environmental toxins may both generate depressive phenotypes as well as lead to anatomical and molecular changes in the brain. Some of these changes are now implicated as potential risk factors for developing neurodegenerative disorders. Toward developing preventative and therapeutic approaches for neurological disorders, he investigated how dietary polyphenols possess anti-inflammatory characteristics in vivo, and how they may promote resilience against the development of mood disorders, with an emphasis on depression and anxiety.

Dr. Stephen Pasternak is a Cognitive Neurologist (specialized in the diagnosis and treatment of neurodegenerative disease) and Director of the Cognitive Neurology and Alzheimer’s Disease Research Centre at Parkwood Institute and a Scientist at the Robarts Research Institute, at the University of Western Ontario (Western University). His laboratory at Robarts uses live cell imaging to understand lysosomal trafficking in Alzheimer’s disease, on blood biomarkers of neurodegenerative disease, and on harnessing protein clearance to treat neurodegenerative disease. At his clinic at Parkwood he sees patients with neurodegenerative disease including Alzheimer’s disease, Lewy Body disease and Parkinson’s Disease Dementia and participates in academic and industrial clinical trials including his own phase 2 trial of Ambroxol to treat Parkinson’s Disease Dementia.

Carmen Peña-Bautista, is a PhD student at the Health Research Institute La Fe (Valencia), where she is part of the Alzheimer Disease Research Group. She obtained the degree in Biochemistry and master's degree in Biomedical Research from University of Valencia. Mrs Peña-Bautista focuses her work on the early and minimally invasive fluid biomarkers for Alzheimer Disease (AD) diagnosis mainly based on oxidative stress biomarkers and omic technologies (epigenomics, lipidomics, metabolomics, and proteomics).

Dr Véronique Perrier obtained her Ph.D in Biochemistry and Biophysics in 1997 at the Pasteur Institute of Paris, on the structural role of zinc in bacterial adenylate kinases. After her Ph.D, she joined the laboratory of Dr Prusiner (Nobel Prize of Medicine 1997) at the University of California San Francisco for a post-doctoral training on prion diseases (Perrier et al., PNAS 2000 and PNAS 2002). In 2001, she joined the Institute of Human Genetics in Montpellier, as a CNRS researcher. Her main project was to develop gene therapy based on lentiviral vectors carrying “dominant negative” PrP (Crozet et al., J. Cell Science, 2004; Toupet et al., PLoSONE 2008, Thermofisher Scientific Biotherapy Prize 2008). From 2005 to 2020, she worked in the Inserm laboratory of Dr. Verdier where she identified oligothiophene-based fluorescent amyloid ligands useful for the detection of all prion isoforms (2 patents, Ayrolles-Torro et al., J. Neurosci. 2011; Imberdis et al., Molecular Neurodegeneration 2016). In 2021, she has joined the Institute of Neurosciences of Montpellier. Her researches are focused on the impact of environmental pollutants on Alzheimer’s disease (Lafon et al., Environ Health Perspect. 2020; Drieu-Chollet Prize 2020) and on neurodevelopment (Wang et al., Environ research 2021).

Dr Richard Perry is a consultant neurologist with a specialist interest in memory disorders and dementias. He completed his medical degree at the medical college of St Bartholomew's Hospital in 1990. His specialist experience in memory disorders and dementia was gained in Cambridge from 1995 to 1999 and in San Francisco from 1999 to 2000. He has been running memory clinics at Charing Cross Hospital in London since 2005 and specialises in early diagnosis and treatment of Alzheimer's disease and other dementias. He leads a team of clinicians running clinical trials for new cutting-edge treatments for dementias at Charing Cross Hospital and has pioneered the use of new diagnostic tests such as amyloid PET scans.

Prof. Dr. med. Oliver Peters, Full Professor at Charité Universitätsmedizin Berlin, is currently chief of the branch Geriatric Neuropsychiatry at the Department of Psychiatry and Psychotherapy, Charité - Campus Benjamin Franklin. He is head of the Memory Clinic and Dementia Prevention Center at Experimental Clinical Research Center (ECRC), Charité - Campus Berlin Buch. He is principal investigator at the German Center for Neurodegenerative Diseases (DZNE) and board member of the German Dementia Competence Network (KND e.V.). He is interested in the establishment of, and has extensively worked on, new biomarkers for early diagnosis of chronic neurodegenerative diseases. He has participated as Principal Investigator in numerous observational and interventional clinical trials.

Ronald C. Petersen, Ph.D., M.D. Professor of Neurology Cora Kanow Professor of Alzheimer’s Disease Research Director, Mayo Alzheimer’s Disease Research Center Mayo Clinic College of Medicine Rochester, MN Dr. Ronald C. Petersen received a Ph.D. from the University of Minnesota and graduated from Mayo Medical School in 1980. He completed an internship in Medicine at Stanford University Medical Center and returned to the Mayo Clinic to complete a residency in Neurology. That was followed by a fellowship in Behavioral Neurology at Harvard University Medical School/Beth Israel Hospital in Boston, Massachusetts. Dr. Petersen was named the Cora Kanow Professor of Alzheimer’s Disease Research and Mayo Clinic Distinguished Investigator in 2011. He is currently the Director of the Mayo Alzheimer’s Disease Research Center and the Mayo Clinic Study of Aging and has authored over 1000 peer-reviewed articles on memory disorders, aging, and Alzheimer’s disease. Dr. Petersen has received the 2004 MetLife Award for Medical Research in Alzheimer’s Disease and the 2005 Potamkin Prize for Research in Picks, Alzheimer’s and Related Disorders of the American Academy of Neurology. In 2012 he received the Khachaturian Award and the Henry Wisniewski Lifetime Achievement Award in 2013 from the Alzheimer’s Association. In 2011 he was appointed by the Secretary of Health and Human Services to serve as the Chair of the Advisory Committee on Research, Care and Services for the National Alzheimer’s Disease Plan.